Mark Schoenebaum, Evercore ISI analyst, discusses his thoughts on the biotech rally. » Read More
Cramer makes the call on viewers' favorite stocks.
The correction may finally be starting: Stocks plunged more than 2% Monday in their worst selloff in 7 weeks. The Nasdaq was the hardest hit, down nearly 3%.
Before I go on vacation for a week I wanted to close the loop and offer some random thoughts on a few things.
OK. I have to put aside the fact that he went to Notre Dame and is a diehard Fighting Irish fan (Go 'SC!), but Regis' trademark rant against Pfizer on "Fast Money" yesterday is too good not to blog it.
Some people may not expect Regis Philbin to be an investor type, but he’s been actively trading since 1983.
Barry James, president of the James Advantage Funds and Hugh Johnson, chairman and CIO of Johnson Illington Advisors discussed their economic outlooks and shared their investment strategies.
Critics have been saying for years that big pharma's been pi..., er, throwing away money on relatively unproductive research and development of new drugs. But a new study shows urine could eventually provide a new revenue stream.
A sigh of relief can be heard by all after two brutal years in the equity markets. But there is something interesting occurring that is gaining little attention. Companies with consistent, stable cash flow, (and not highly leveraged) are underperforming more risky leveraged assets. What's going on?
Daniel Loeb's Third Point fund, with $1.8 billion in assets under management, has had a successful second quarter. In its most recent letter to investors, acquired by CNBC, the hedge fund reports the following returns and holdings.
In sports, it’s important to play defense AND offense. In investing, the same holds true. After months of defensive strategies, consider your overall offensive strategy as we seem to be seeing an apparent turn in the world's economic fortunes.
Following are the week’s biggest winners and losers. Find out why shares of Nike and American Superconductor popped while Exxon Mobil and Pfizer dropped.
As the markets continue to surge ahead, the equities on the Nasdaq and New York Stock Exchange continue to hit new highs. 61 companies on the NYSE and a whopping 116 companies on the Nasdaq hit new 52-week highs yesterday.
Dividend yields in the S&P 500 are down since late June, as a 6% rally for the US equity index this month has pushed yields lower, and companies remain cautious about increasing their dividend payouts.
Apparently, Nancy Reagan isn't the only one saying no to drugs. Options Traders appear to be living in an 80s PSA as well, shunning shares of Pfizer through some heavy put buying.
Shares of Acadia Pharmaceuticals skyrocketed along with heavy options activity at the end of last week.
Here's our Fast Money Final Trade. Our gang gives you Monday's best trades, right now!
The latest batch of earnings took a toll on the market Friday but the Dow still pulled off a gain in the final half hour of trading, capping its best two-week performance since 2000. Microsoft shares fell more than 8%.
Stocks took a hit Friday as a drop in consumer sentiment exacerbated losses triggered by a disappointing round of earnings from Microsoft, Amazon and AmEx. But the Dow poked higher in afternoon trading Microsoft shares fell nearly 10%.
Stocks skidded Friday as a drop in consumer sentiment exacerbated losses triggered by a disappointing round of earnings from American Express, Amazon and Microsoft.
Hailing from four separate corners of the U.S. economy, Apple, Caterpillar, Starbucks, and Merck all beat the street. Throw in the banks and now you’re talking five corners. It’s bullish — 90 percent of the American workforce and rising business may be doing some spending and risk-taking after all. I like this story a lot.